Chromatin Bioscience has announced a research collaboration with Purespring Therapeutics, a clinical-stage precision nephrology company, to develop highly cell-selective synthetic promoters for targeted gene therapies aimed at preserving kidney function. The partnership combines Chromatin's proprietary chromatinLENS platform with Purespring's innovative approach to treating kidney diseases through precise genetic interventions.
Advancing Precision Gene Therapy Through Synthetic Promoters
The collaboration focuses on developing synthetic promoters that enable precise and durable gene expression in target cell types relevant to Purespring's therapeutic strategy. Chromatin's chromatinLENS platform identifies highly specific gene regulatory elements from the dark genome and integrates them into synthetic promoters optimized for target cell selectivity and expression durability.
"Purespring's approach to gene therapy aligns well with our mission to provide precise gene control systems that support advanced, tissue-targeted therapeutics," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We are excited to support their efforts with our platform and help unlock the full therapeutic potential of next-generation gene therapies."
The partnership aims to enhance the safety and efficacy of gene delivery through the integration of rationally designed synthetic promoters, which are critical components in gene therapies where spatial and temporal control of transgene expression is essential for therapeutic success.
Targeting Kidney Disease Through Podocyte-Directed Therapy
Purespring Therapeutics operates through its proprietary GlomThera platform, which delivers genetic therapies directly to the podocyte, offering a novel approach to treating kidney diseases. The company's pipeline targets multiple renal indications with significant unmet medical need.
Purespring's lead program, PS-002, offers a highly differentiated approach for patients with IgA nephropathy (IgAN). By precisely targeting the site of disease, Purespring aims to transform the trajectory of kidney disease so patients can live fuller, healthier lives.
Strategic Partnership Expansion
This collaboration with Purespring represents another milestone in Chromatin Bioscience's growing network of partnerships across the gene therapy landscape. The partnership highlights the versatility of Chromatin's synthetic promoter technology across various therapeutic areas.
Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank, and has raised £115 million ($150 million) to date. The company's clinical-stage status and substantial funding demonstrate the commercial potential of precision nephrology approaches.
While specific program details remain confidential, the collaboration is designed to advance the development of targeted, first-in-class genetic therapies that could address significant unmet needs in kidney disease treatment.
